Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III
This article was originally published in Scrip
Executive Summary
Transgene SA's share price has received a welcome boost this week on two separate pieces of news. Transgene's development partner SillaJen Inc. has begun the first Phase III trial of the oncolytic immunotherapy Pexa-Vec in patients with advanced liver cancer. Also, the company unveiled a new strategic development plan as well as the securing of €30m new financing.
You may also be interested in...
Transgene’s Moment Of Truth Approaches
French biotech Transgene SA has been through a few transformations in its 37-year history, and the past couple of years have been particularly rocky. However, chairman and CEO Philippe Archinard sees light at the end of the tunnel as the new era of combination immunotherapy arrives.
NICE Clears Amgen’s Imlygic At Second Attempt, Combo Results Keenly Awaited
A completely new form of therapy, the use of viruses to kill cancer cells, is now recommended by NICE for use in melanoma patients in England in final draft guidance, although its future therapeutic and commercial success may depend on positive findings from ongoing combination studies with checkpoint inhibitors and other immunotherapies.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.